Haemophilus influenzae infection future or investigational therapies: Difference between revisions
Created page with "__NOTOC__ {{Hemophilus influenza serotype B infection}} {{CMG}} ==Future and Investigational Therapies== Elimination of persistent Hib disease in the United States. Current..." |
m Changes made per Mahshid's request |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Haemophilus influenzae infection}} | ||
{{CMG}} | {{CMG}} | ||
| Line 6: | Line 6: | ||
==Future and Investigational Therapies== | ==Future and Investigational Therapies== | ||
Currently available conjugate vaccines differ in immuno-genicity in very young children and possibly in duration of antibody persistence, raising questions about long-term efficacy (>5 years), optimal use, and schedules. Monitoring the possible emergence of disease due to other serotypes. Problems with serotyping of H. influenzae in state health departments. Development of rapid molecular assays for detection and molecular subtyping of all Hi strains. The cost of Hib conjugate vaccines has limited their use in developing countries even though Hib is a major cause of morbidity and mortality. | |||
Evaluating the characteristics of Hib vaccines associated with prevention of carriage and invasive disease will facilitate application of this technology to development of conjugate vaccines for other organisms with polysaccharide capsules (such as the meningococcus, pneumococcus, and group B streptococcus). Further evaluation of herd immunity effects may lead to insight into vaccination strategies that optimize protection against invasive disease and transmission of Hib organisms. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs overview]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Bacterial diseases]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 17:52, 18 September 2017
|
Haemophilus influenzae infection Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Future and Investigational Therapies
Currently available conjugate vaccines differ in immuno-genicity in very young children and possibly in duration of antibody persistence, raising questions about long-term efficacy (>5 years), optimal use, and schedules. Monitoring the possible emergence of disease due to other serotypes. Problems with serotyping of H. influenzae in state health departments. Development of rapid molecular assays for detection and molecular subtyping of all Hi strains. The cost of Hib conjugate vaccines has limited their use in developing countries even though Hib is a major cause of morbidity and mortality.
Evaluating the characteristics of Hib vaccines associated with prevention of carriage and invasive disease will facilitate application of this technology to development of conjugate vaccines for other organisms with polysaccharide capsules (such as the meningococcus, pneumococcus, and group B streptococcus). Further evaluation of herd immunity effects may lead to insight into vaccination strategies that optimize protection against invasive disease and transmission of Hib organisms.